Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518

被引：0
|
作者：
Rosenstock, Julio [1 ]
机构：
[1] Dallas Diabet Res Ctr, Dallas, TX 75230 USA
来源：
DIABETES CARE | 2021年 / 44卷 / 11期
关键词：
GLARGINE;
D O I：
10.2337/dci21-0004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E196 / E197
页数：2
相关论文
共 50 条
  • [41] Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy
    Jendle, Johan
    Testa, Marcia A.
    Martin, Sherry
    Jiang, Honghua
    Milicevic, Zvonko
    DIABETES OBESITY & METABOLISM, 2016, 18 (10): : 999 - 1005
  • [42] Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin
    Alexopoulos, Anastasia-Stefania
    Buse, John B.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 98 : 104 - 111
  • [43] Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
    Berlie, Helen
    Hurren, Kathryn M.
    Pinelli, Nicole R.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 165 - 174
  • [44] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1-5
    Vilsboll, T.
    Bangsgaard, K. O.
    Fu, A.
    Kellerer, M.
    Sogaard, S. B.
    Goldenberg, R.
    DIABETOLOGIA, 2024, 67 : S9 - S9
  • [45] Near-Normalization of Glycemic Control in Patients with Type 2 Diabetes with a Glucagon-like Peptide-1 Receptor Agonist in Combination with Exercise Training: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
    Mensberg, Pernille
    Nyby, Signe
    Jorgensen, Peter G.
    Storgaard, Heidi
    Sivertsen, Jacob
    Jensen, Magnus T.
    Holst, Jens Juul
    Kiens, Bente
    Richter, Erik A.
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES, 2014, 63 : A182 - A182
  • [46] Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes
    Gomez-Peralta, Fernando
    Al-Ozairi, Ebaa
    Jude, Edward B.
    Li, Xiaoying
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1445 - 1452
  • [47] The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
    Sanjoy K Paul
    Kerenaftali Klein
    David Maggs
    Jennie H Best
    Cardiovascular Diabetology, 14
  • [48] The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
    Paul, Sanjoy K.
    Klein, Kerenaftali
    Maggs, David
    Best, Jennie H.
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [49] Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use-ONWARDS 1-5
    Vilsboll, Tina
    Bangsgaard, Katrine O.
    Fu, Ariel
    Kellerer, Monika
    Sogaard, Stinne B.
    Goldenberg, Ronald
    DIABETES, 2024, 73
  • [50] Glucagon-like Peptide-1 Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Li, Wei-Xin
    Gou, Jian-Feng
    Tian, Jin-Hui
    Yan, Xiang
    Yang, Lin
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2010, 71 (04): : 211 - 238
12345